MARY’S, ANTIGUA- Esports Entertainment Group, Inc. (OTCQB:GMBL) (or the “Company”), a licensed online gambling company with a specific focus on esports wagering and 18+ gaming, is pleased to announce Affiliate Marketing Agreements with 34 additional esports teams as the Company continues to ramp up affiliate marketing activities in support of its recent launch of vie.gg, the world’s first and most transparent esports betting exchange.
NEW YORK (GenomeWeb) – Kromatid said today that it has received a Fast-Track Small Business Innovation Research (SBIR) grant from the National Human Genome Research Institute to further develop its proprietary single-cell structural genomics platform.
BuildingDNA announced today that Greg Brooks has joined the company as Vice President of Sales. Brooks comes to BuildingDNA with more than 20 years of experience in the telecom and public safety spaces including leading 9-1-1 infrastructure provider West Safety Services.
KromaTiD, Inc. announced today that it has joined the National Institutes of Standards and Technology Genome Editing Consortium, a newly launched public/private partnership (https://www.nist.gov/programs-projects/nist-genome-editing-consortium). The Consortium supports the emerging gene editing market and regulatory agency needs for standardized measurements of gene edits, editing by-products and the risks of utilizing genome editing technologies in research, commercial and therapeutic products.
BuildingDNA (www.BuildingDNA.com), the leader in visual intelligence for smarter, safer buildings, today announced that its platform has been selected as winner of the “Overall Smart City Solution of the Year” award from IoT Breakthrough, an independent organization that recognizes the top companies, technologies and products in the global Internet-of-Things (IoT) market today.
KromaTiD, the provider of Directional Genomic Hybridization and Pinpoint FISH products, successfully completed its Series A round as of May 31st, 2017. Funds from this round will be used to grow sales and expand marketing of KromaTiD’s proprietary products and services, as well as building operations to meet market demand for precision medicine products.
KromaTiD Inc. announced today that it will be participating in the 2018 American Cytogenomics Conference (ACC) from June 10-13 in Snowbird, Utah. The ACC is a biennial gathering intended to connect cytogenetic industry researchers and professionals with the latest technologies, discoveries, and ideas throughout the field.